Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug industry and health care reform

Executive Summary

Congressional staffers say representatives from individual companies have expressed an eagerness to cooperate in the legislative process. Several firms have offered to support a national prescription drug benefit. PMA's current position endorses a government-funded benefit for the poor, elderly and disabled. Merck has scheduled a briefing in Washington for securities analysts on Jan. 15 to explain its health legislative policies for the new Congress. The firm supports broad prescription drug coverage and payment of royalties to the government for drugs developed with government funding. It opposes global spending limits on health care or price controls.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021965

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel